AP NEWS
Listen
  • U.S. News
  • World News
  • Politics
  • Sports
  • Entertainment
  • Business
  • Technology
  • Health
  • Science
  • Oddities
  • Lifestyle
  • Photography
  • Videos
Listen
  1. AP Top News
  2. U.S. News
  3. World NewsAfricaAsia PacificAustraliaEuropeLatin AmericaMiddle East
  4. PoliticsPresident BidenElection coverageCongressSupreme Court
  5. SportsSuper BowlTennisNBANHLCollege basketballMLB
  6. EntertainmentFilm ReviewsMoviesMusicTelevisionFashion
  7. BusinessU.S. economyFinancial markets

  8. Videos
  9. Technology
  10. HealthCOVID-19
  11. MoreAP InvestigationsClimate and environmentOdditiesPhotographyTravelScienceAP Fact CheckLifestyleReligionPress Releases
  • Trending News
  • U.S. winter storms
  • Grammy Awards
  • Super Bowl
  • Russia-Ukraine war
ADVERTISEMENT

Drug approvals

Click to copy

Speedier drug approvals hit slowdown as FDA faces scrutiny

By MATTHEW PERRONEDecember 7, 2022 GMT

WASHINGTON (AP) — Expedited drug approvals slowed this year as the Food and Drug Administration's controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders.

Medicare copays for new Alzheimer’s drug could reach $11,500

By RICARDO ALONSO-ZALDIVAR and MATTHEW PERRONEJune 11, 2021 GMT

WASHINGTON (AP) — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.

Keeps Review - Do Keeps Hair Loss Treatments Work? (Keeps.com Review)

Perform InsiderNovember 6, 2020 GMT

New York, New York - ( NewMediaWire ) - November 06, 2020 - Keeps is an online-only subscription service that specializes in treating male baldness. The company offers two of the most popular anti-hair loss medications that are also approved by the FDA...

ADVERTISEMENT

FDA says Novartis withheld data problem before drug approval

By LINDA A. JOHNSONAugust 6, 2019 GMT

TRENTON, N.J. (AP) — U.S. regulators want to know why Novartis didn't disclose a problem with testing data until after the Swiss drugmaker's $2...

ADVERTISEMENT
AP NEWS
  1. Top Stories
  2. Video
  3. Contact Us
  4. Accessibility Statement
Download AP NEWS
Connect with the definitive source for global and local news
More from AP
  1. ap.org
  2. AP Insights
  3. AP Definitive Source Blog
  4. AP Images Spotlight
  5. AP Explore
  6. AP Books
  7. AP Stylebook
Follow AP
The Associated Press
  1. About
  2. Contact
  3. Customer Support
  4. Careers
  5. Terms & Conditions
  6. Privacy
All contents © copyright 2023 The Associated Press. All rights reserved.